Pricing Log in Create free account
Saturday 31 October 2026 Export BMY’s income statement to Excel — free account

Bristol Myers Squibb Company

BMY Healthcare Drug Manufacturers General

Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue grew 5.74%, EPS grew 153.1%, free cash flow fell 13.2% and total debt fell 12.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.

62.55 1.16 +1.89%
Market cap
$125.4B
P/E
13.8×
Fwd P/E
11.9×
Dividend yield
4.03%
F-score
8/9
Altman Z
2.14
Beneish M
−2.69
Dividend safety
63/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Filings

Bristol Myers Squibb Company 10-Q filed Jul 31, 2025

Fiscal Q2 2025 · Period ended Jun 30, 2025 · Filed · accepted 12:17 PM ET · Document on sec.gov · Filing index

Nothing in this filing raised a red flag. The document itself is on sec.gov.

Read the filing on sec.gov